Galmed Pharmaceuticals Ltd. - Ordinary Shares, NIS 1.80 par value per share (GLMD)
CUSIP: M47238148
Q3 2025 13F Holders as of 30 Sep 2025
- Type / Class
- Equity / Ordinary Shares, NIS 1.80 par value per share
- Shares outstanding
- 5,591,387
- Total 13F shares
- 72,824
- Share change
- -3,163
- Total reported value
- $102,011
- Price per share
- $1.38
- Number of holders
- 13
- Value change
- -$18,462
- Number of buys
- 3
- Number of sells
- 7
Quarterly Holders Quick Answers
What is CUSIP M47238148?
CUSIP M47238148 identifies GLMD - Galmed Pharmaceuticals Ltd. - Ordinary Shares, NIS 1.80 par value per share in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP M47238148:
Top shareholders of GLMD - Galmed Pharmaceuticals Ltd. - Ordinary Shares, NIS 1.80 par value per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| CVI Investments, Inc. |
13D/G
|
— |
3.1%
|
173,333
|
$346,666 | $0 | 30 Sep 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0.6%
|
33,573
|
$61,774 | — | 30 Jun 2025 | |
| Allen Baharaff |
13D/G
|
— |
2.6%
|
44,128
|
$60,455 | $0 | 31 Dec 2024 | |
| Schonfeld Strategic Advisors LLC |
13F
|
Company |
0.41%
|
23,194
|
$42,676 | — | 30 Jun 2025 | |
| Cambridge Investment Research Advisors, Inc. |
13F
|
Company |
0.18%
|
10,132
|
$19,000 | — | 30 Jun 2025 | |
| UBS Group AG |
13F
|
Company |
0.12%
|
6,903
|
$12,702 | — | 30 Jun 2025 | |
| SBI Securities Co., Ltd. |
13F
|
Company |
0.04%
|
2,116
|
$3,893 | — | 30 Jun 2025 | |
| Physician Wealth Advisors, Inc. |
13F
|
Company |
0%
|
23
|
$43 | — | 30 Jun 2025 | |
| Federation Des Caisses Desjardins du Quebec |
13F
|
Individual |
0%
|
14
|
$26 | — | 30 Jun 2025 | |
| RAYMOND JAMES FINANCIAL INC |
13F
|
Company |
0%
|
12
|
$22 | — | 30 Jun 2025 | |
| WELLS FARGO & COMPANY/MN |
13F
|
Company |
0%
|
9
|
$17 | — | 30 Jun 2025 | |
| OSAIC HOLDINGS, INC. |
13F
|
Company |
0%
|
5
|
$9 | — | 30 Jun 2025 | |
| Allworth Financial LP |
13F
|
Company |
0%
|
2
|
$4 | — | 30 Jun 2025 | |
| TD Waterhouse Canada Inc. |
13F
|
Company |
0%
|
2
|
$4 | — | 30 Jun 2025 | |
| Dogwood Wealth Management LLC |
13F
|
Company |
0%
|
1
|
$2 | — | 30 Jun 2025 | |
| ELEVATION WEALTH PARTNERS, LLC |
13F
|
Company |
0%
|
1
|
$2 | — | 30 Jun 2025 |
Institutional Holders of Galmed Pharmaceuticals Ltd. - Ordinary Shares, NIS 1.80 par value per share (GLMD) as of Q3 2025
As of 30 Sep 2025,
Galmed Pharmaceuticals Ltd. - Ordinary Shares, NIS 1.80 par value per share (GLMD) was held by
13 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
72,824 shares.
The largest 10 holders included
CITADEL ADVISORS LLC, TWO SIGMA INVESTMENTS, LP, UBS Group AG, MORGAN STANLEY, Wealthspire Advisors, LLC, SBI Securities Co., Ltd., Federation des caisses Desjardins du Quebec, WELLS FARGO & COMPANY/MN, OSAIC HOLDINGS, INC., and TD Waterhouse Canada Inc..
This page lists
13
institutional shareholders reporting positions in this security
for the Q3 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q3 2025 vs Q2 2025 Across Filers
Q2 2025 holders
14
Q3 2025 holders
13
Holder diff
-1
| Investor | Q2 2025 Shares | Q3 2025 Shares | Share Diff | Share Chg % | Q2 2025 Value $ | Q3 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.